AGP Executive Report
Last update: 5 hours agoCardiology Trial Update: The LIBREXIA ACS study found milvexian (a factor XIa inhibitor) did not reduce major cardiovascular events after acute coronary syndrome, with no rise in intracranial or fatal bleeding—prompting earlier trial discontinuation for futility. Pediatric Care: A new imaging roadmap for pediatric portal hypertension lays out a full diagnostic and follow-up chain (ultrasound/Doppler, elastography, CT, MRI) and highlights image-guided options that can sometimes restore normal liver blood flow without transplant. Lipid Management After Heart Attack: The AMUNDSEN trial reports that starting evolocumab immediately after myocardial infarction improves LDL-cholesterol goal achievement, but did not show better early survival or fewer unplanned cardiovascular hospitalizations. Public Health Watch: Kenya’s dengue cases are rising again, with 1,679 reported (mainly Garissa and Wajir), and health agencies urge standard mosquito-bite precautions. France Health Policy: Édouard Philippe and François Hollande clash on how to tackle France’s debt—Philippe pushing strict spending control, Hollande backing tax increases for the wealthiest.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
